Wang Lin-Run, Huang Ming-Zhu, Xu Nong, Shentu Jian-Zhong, Liu Jian, Cai Jie
First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
J Zhejiang Univ Sci B. 2005 May;6(5):446-50. doi: 10.1631/jzus.2005.B0446.
To determine the pharmacokinetics of gemcitabine (2',2'-difluorodeoxycytidine) in Chinese non-small-cell lung cancer (NSCLC) patients. Six study subjects were administered gemcitabine at a fixed dose rate of 10 mg/m(2) per min (1200 mg/m(2), two hours infusion), and carboplatin and plasma gemcitabine concentrations were measured by ion-pair reversed-phase high-performance liquid chromatography (HPLC). 3P97 Pharmaceutical Kinetics Software was used for the calculation of pharmacokinetic parameters. The obtained mean parameters, elimination half life (t(1/2)) (10.67+/-3.38 min), area under the curve (AUC) (7.55+/-1.53 (microg x h)/ml), and clearance (CL) (3940.05+/-672.08 ml/min), were consistent with those reported in literature. The hematologic toxicology result showed that the regimen was effective on and tolerated by the patients.
为确定吉西他滨（2'，2'-二氟脱氧胞苷）在中国非小细胞肺癌（NSCLC）患者中的药代动力学。6名研究对象以10mg/m²每分钟的固定剂量率（1200mg/m²，两小时输注）给予吉西他滨，并通过离子对反相高效液相色谱法（HPLC）测量卡铂和血浆吉西他滨浓度。使用3P97药物动力学软件计算药代动力学参数。获得的平均参数，消除半衰期（t(1/2)）（10.67±3.38分钟）、曲线下面积（AUC）（7.55±1.53（μg×h）/ml）和清除率（CL）（3940.05±672.08ml/分钟）与文献报道一致。血液学毒理学结果表明该方案对患者有效且耐受性良好。
